Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics
Status:
Withdrawn
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of Tekturna (aliskiren), in combination
with an ACE and calcium channel blocker in hypertensive patients diagnosed with Type II
diabetes.